

START UP / THE NEXT BIG THING: THE LIST

Regentis

Year of Establishment: 2004

Field: Medical Equipment

Capital: USD 15 Million

Investors: SCP Vitalife, Medica Venture Partners, Royal DSM through its venturing subsidiary the Crossroad Fund, and the Technion Investment Opportunities Fund

Number of Employees: 15

CEO: Alastair Clemow



Regentis Biomaterials will help those who suffer from knee pain due to cartilage degeneration, a phenomenon known to every infantry brigade fighter as well as those who play soccer every Friday.

Regentis has developed a polymer liquid gel that combines natural and artificial materials, emulating natural cartilage and creating a better environment for natural renewal.

The Choice: The Western world faces an increasingly aging population with a greater need for orthopedic treatments. Regentis' unique substance draws investors and arouses tremendous interest in the world of orthopedics.

What Does It Do? Regentis' treatment is aimed at senior citizens as well as those suffering from sports injuries or accidents. "Our products are based on studies carried out by Prof. Dror Seliktar from the Technion – Israel Institute of Technology, who currently serves as the company's Chief Scientist," explains CEO Alastair Clemow. "Most of the substances currently available on the market are either synthetic or natural and each has its advantages and disadvantages."

"The polymer we have developed is a combination of natural and artificial substances and behaves like an ice pack. It is injected into the body in gel form and solidifies later. Once in the body, it is absorbed gradually over a period of 6 to 12 months allowing for the renewal of quality cartilage tissue that resembles natural cartilage and has optimal integration with the existing cartilage."

Regentis Biomaterials is in the final stages of clinical research in Europe and Israel, and hopes to have the product on the market within two years.

Present Situation: In the last few weeks, Regentis has secured \$10 million US in capital from existing investors – SCP Vitalife, Medica Venture Partners, the Technion Investment Opportunities Fund, Royal DSM through its venture subsidiary and the Crossroad Fund.

Our Plan: "Clinical trials are already being carried out in Europe and will be increased and expanded to the U.S. over the next two years," says Clemow. "We are also establishing a database of clinical results that will serve as a basis for clinical trials in the United States."

